Vicinitas Therapeutics
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- vicinitatx.com
- Total Funding
- $65.0M
- Last Round
- $65.0M Series AJul 2022
About
Vicinitas Therapeutics is a South San Francisco-based biotechnology company pioneering a novel class of small-molecule therapeutics called DUBTACs — Deubiquitinase Targeting Chimeras — that stabilize disease-relevant proteins. The company launched in 2022 with $65 million in funding from Deerfield Management and other life sciences investors.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account